MSGV-1D3-28Z All ITAMs intact Citations (4)
Originally described in: Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells.Kochenderfer JN, Yu Z, Frasheri D, Restifo NP, Rosenberg SA Blood. 2010 Nov 11;116(19):3875-86. doi: 10.1182/blood-2010-01-265041. Epub 2010 Jul 14. PubMed Journal
Articles Citing MSGV-1D3-28Z All ITAMs intact
| Articles |
|---|
| Cellular origins and genetic landscape of cutaneous gamma delta T cell lymphomas. Daniels J, Doukas PG, Escala MEM, Ringbloom KG, Shih DJH, Yang J, Tegtmeyer K, Park J, Thomas JJ, Selli ME, Altunbulakli C, Gowthaman R, Mo SH, Jothishankar B, Pease DR, Pro B, Abdulla FR, Shea C, Sahni N, Gru AA, Pierce BG, Louissaint A Jr, Guitart J, Choi J. Nat Commun. 2020 Apr 14;11(1):1806. doi: 10.1038/s41467-020-15572-7. PubMed |
| Host B cells escape CAR-T immunotherapy by reversible downregulation of CD19. Fioretti S, Matson CA, Rosenberg KM, Singh NJ. Cancer Immunol Immunother. 2022 Jun 26. pii: 10.1007/s00262-022-03231-3. doi: 10.1007/s00262-022-03231-3. PubMed |
| Targeting Macrophages with CAR T Cells Delays Solid Tumor Progression and Enhances Antitumor Immunity. Sanchez-Paulete AR, Mateus-Tique J, Mollaoglu G, Nielsen SR, Marks A, Lakshmi A, Khan JA, Wilk CM, Pia L, Baccarini A, Merad M, Brown BD. Cancer Immunol Res. 2022 Nov 2;10(11):1354-1369. doi: 10.1158/2326-6066.CIR-21-1075. PubMed |
Fully murine CD105-targeted CAR-T cells provide an immunocompetent model for CAR-T cell biology.
Lontos K, Wang Y, Colbert M, Kumar A, Joshi S, Philbin M, Wang Y, Frisch A, Lohmueller J, Rivadeneira DB, Delgoffe GM.
Oncoimmunology. 2022 Oct 18;11(1):2131229. doi: 10.1080/2162402X.2022.2131229. eCollection 2022.
PubMed
Associated Plasmids |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.